See more : Monterey Bio Acquisition Corporation (MTRY) Income Statement Analysis – Financial Results
Complete financial analysis of Psychemedics Corporation (PMD) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Psychemedics Corporation, a leading company in the Medical – Diagnostics & Research industry within the Healthcare sector.
You may be interested
- Emyria Limited (EMD.AX) Income Statement Analysis – Financial Results
- Chugai Ro Co., Ltd. (1964.T) Income Statement Analysis – Financial Results
- Penta Teknoloji Urunleri Dagitim Ticaret A.S. (PENTA.IS) Income Statement Analysis – Financial Results
- Danaos Corporation (DAC) Income Statement Analysis – Financial Results
- XP Power Limited (XPP.L) Income Statement Analysis – Financial Results
Psychemedics Corporation (PMD)
About Psychemedics Corporation
Psychemedics Corporation provides testing services for the detection of drugs of abuse through the analysis of hair samples in the United States, Brazil, and internationally. The company offers screening and confirmation by mass spectrometry using industry-accepted practices for cocaine, marijuana, and PCP; amphetamines, including ecstasy, eve, and Adderall; opiates, such as heroin, hydrocodone, hydromorphone, oxycodone, oxymorphone, and codeine; synthetic cannabinoids comprising K2, Spice, and Blaze; benzodiazepines consisting of Xanax, Valium, and Ativan; and nicotine and Fentanyl. Its testing results provide quantitative information that could indicate the approximate amount of drug ingested, as well as historical data that could show a pattern of individual drug use over a longer period-of-time. The company offers its services to employers for applicant and employee testing; and treatment professionals, law enforcement agencies, school administrators, and parents concerned about their children's drug use. Psychemedics Corporation was incorporated in 1986 and is headquartered in Acton, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 | 1992 | 1991 | 1990 | 1989 | 1988 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 22.10M | 25.24M | 24.91M | 21.36M | 37.68M | 42.67M | 39.70M | 38.98M | 26.98M | 29.20M | 26.87M | 25.22M | 24.09M | 20.11M | 16.95M | 22.95M | 24.57M | 23.43M | 21.39M | 18.94M | 16.00M | 16.07M | 15.73M | 19.22M | 19.60M | 17.70M | 15.40M | 12.20M | 10.10M | 8.70M | 6.60M | 4.00M | 2.50M | 1.70M | 300.00K | 100.00K |
| Cost of Revenue | 13.69M | 15.95M | 14.65M | 16.47M | 21.23M | 22.06M | 19.88M | 17.53M | 14.26M | 14.07M | 11.48M | 10.97M | 9.62M | 8.07M | 7.35M | 9.60M | 9.89M | 9.37M | 8.81M | 8.49M | 7.63M | 7.02M | 7.82M | 8.90M | 7.20M | 6.50M | 5.40M | 4.50M | 4.20M | 3.30M | 2.40M | 1.60M | 1.40M | 1.00M | 1.30M | 300.00K |
| Gross Profit | 8.41M | 9.29M | 10.26M | 4.89M | 16.44M | 20.62M | 19.82M | 21.45M | 12.72M | 15.14M | 15.39M | 14.25M | 14.47M | 12.04M | 9.61M | 13.35M | 14.68M | 14.06M | 12.58M | 10.45M | 8.37M | 9.05M | 7.92M | 10.32M | 12.40M | 11.20M | 10.00M | 7.70M | 5.90M | 5.40M | 4.20M | 2.40M | 1.10M | 700.00K | -1.00M | -200.00K |
| Gross Profit Ratio | 38.07% | 36.81% | 41.21% | 22.87% | 43.64% | 48.32% | 49.93% | 55.03% | 47.14% | 51.83% | 57.29% | 56.50% | 60.08% | 59.88% | 56.68% | 58.17% | 59.74% | 60.00% | 58.80% | 55.17% | 52.33% | 56.32% | 50.32% | 53.72% | 63.27% | 63.28% | 64.94% | 63.11% | 58.42% | 62.07% | 63.64% | 60.00% | 44.00% | 41.18% | -333.33% | -200.00% |
| Research & Development | 1.14M | 1.33M | 1.13M | 1.28M | 1.57M | 1.55M | 1.36M | 1.42M | 1.63M | 1.35M | 825.10K | 825.52K | 607.41K | 481.43K | 467.44K | 474.62K | 489.01K | 444.53K | 335.77K | 329.42K | 305.68K | 358.10K | 608.19K | 475.70K | 500.00K | 500.00K | 400.00K | 400.00K | 400.00K | 400.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 7.19M | 5.86M | 6.13M | 6.10M | 7.22M | 6.43M | 5.64M | 4.97M | 4.56M | 4.47M | 4.16M | 3.95M | 3.95M | 4.20M | 3.60M | 4.52M | 7.05M | 6.05M | 5.91M | 5.79M | 6.13M | 6.76M | 6.98M | 7.42M | 7.10M | 6.40M | 5.90M | 4.40M | 3.70M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 3.00M | 3.19M | 2.80M | 3.58M | 4.66M | 5.03M | 4.67M | 4.96M | 5.05M | 4.63M | 4.70M | 4.54M | 4.12M | 2.95M | 2.96M | 3.65M | 12.50K | 0.00 | 0.00 | 0.00 | 2.82B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 10.19M | 9.05M | 8.93M | 9.67M | 11.88M | 11.46M | 10.31M | 9.93M | 9.61M | 9.10M | 8.86M | 8.49M | 8.06M | 7.15M | 6.56M | 8.17M | 7.05M | 6.05M | 5.91M | 5.79M | 6.13M | 6.76M | 6.98M | 7.42M | 7.10M | 6.40M | 5.90M | 4.40M | 3.70M | 2.80M | 2.90M | 2.70M | 2.30M | 2.60M | 0.00 | 1.70M |
| Other Expenses | 0.00 | 43.00K | -1.03M | -140.00K | 58.00K | 43.00K | 20.00K | -134.00K | -124.59K | -56.58K | 92.27K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.30M | 1.00M | 700.00K | 500.00K | 600.00K | 400.00K | 300.00K | 200.00K | 200.00K | 200.00K | 100.00K | 100.00K |
| Operating Expenses | 11.33M | 10.37M | 10.06M | 10.95M | 13.45M | 13.01M | 11.67M | 11.34M | 11.25M | 10.45M | 9.69M | 9.32M | 8.67M | 7.63M | 7.03M | 8.64M | 7.54M | 6.49M | 6.25M | 6.12M | 6.43M | 7.11M | 7.59M | 7.89M | 8.90M | 7.90M | 7.00M | 5.30M | 4.70M | 3.60M | 3.20M | 2.90M | 2.50M | 2.80M | 100.00K | 1.80M |
| Cost & Expenses | 25.02M | 26.32M | 24.70M | 27.43M | 34.68M | 35.06M | 31.54M | 28.87M | 25.50M | 24.52M | 21.16M | 20.29M | 18.29M | 15.69M | 14.37M | 18.24M | 17.43M | 15.86M | 15.06M | 14.61M | 14.06M | 14.13M | 15.41M | 16.79M | 16.10M | 14.40M | 12.40M | 9.80M | 8.90M | 6.90M | 5.60M | 4.50M | 3.90M | 3.80M | 1.40M | 2.10M |
| Interest Income | 0.00 | 0.00 | 49.00K | 75.00K | 134.00K | 149.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.89K | 5.35K | 23.09K | 45.32K | 308.03K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 49.00K | 75.00K | 59.00K | 106.00K | 0.00 | 134.00K | 124.59K | 56.58K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 2.67M | 3.32M | 3.69M | 3.63M | 2.91M | 3.06M | 2.81M | 2.29M | 1.73M | 1.05M | 872.17K | 586.97K | 370.02K | 284.91K | 336.80K | 331.39K | 347.13K | 287.44K | 408.97K | 533.59K | 871.99K | 1.14M | 1.27M | 1.28M | 1.30M | 1.00M | 700.00K | 500.00K | 600.00K | 400.00K | 300.00K | 200.00K | 200.00K | 200.00K | 100.00K | 100.00K |
| EBITDA | -251.00K | 2.23M | 3.90M | -2.44M | 5.91M | 7.61M | 10.96M | 12.40M | 2.75M | 5.49M | 6.58M | 5.52M | 6.17M | 4.70M | 2.92M | 5.04M | 7.49M | 7.85M | 6.74M | 4.86M | 2.81M | 3.08M | 1.59M | 3.71M | 4.80M | 4.30M | 3.70M | 2.90M | 1.80M | 2.20M | 1.30M | -300.00K | -1.20M | -1.90M | -1.00M | -400.00K |
| EBITDA Ratio | -1.14% | -4.29% | 0.84% | -28.40% | 7.96% | 17.83% | 20.55% | 25.94% | 5.45% | 16.06% | 21.24% | 19.57% | 25.61% | 23.37% | 15.24% | 21.95% | 30.47% | 33.51% | 31.48% | 25.62% | 17.57% | 18.31% | 10.11% | 16.88% | 24.49% | 20.90% | 20.78% | 20.49% | 13.86% | 22.99% | 19.70% | -10.00% | -48.00% | -111.76% | -333.33% | -2,000.00% |
| Operating Income | -2.92M | -1.08M | -3.48M | -6.07M | 84.00K | 7.65M | 8.16M | 10.11M | 1.47M | 4.69M | 5.71M | 4.94M | 5.80M | 4.41M | 2.58M | 4.71M | 7.14M | 7.56M | 6.33M | 4.33M | 1.94M | 1.94M | 323.19K | 2.43M | 3.50M | 3.30M | 3.00M | 2.40M | 1.20M | 1.80M | 1.00M | -500.00K | -1.40M | -2.10M | -1.10M | -2.00M |
| Operating Income Ratio | -13.22% | -4.29% | -13.97% | -28.40% | 0.22% | 17.93% | 20.55% | 25.94% | 5.45% | 16.06% | 21.24% | 19.57% | 24.08% | 21.95% | 15.24% | 20.51% | 29.06% | 32.29% | 29.58% | 22.87% | 12.12% | 12.05% | 2.05% | 12.64% | 17.86% | 18.64% | 19.48% | 19.67% | 11.88% | 20.69% | 15.15% | -12.50% | -56.00% | -123.53% | -366.67% | -2,000.00% |
| Total Other Income/Expenses | -517.00K | 43.00K | -1.03M | -140.00K | 58.00K | 43.00K | 20.00K | -134.00K | -124.00K | -57.00K | 92.27K | 1.89K | 5.35K | 23.09K | 45.32K | 308.03K | 416.65K | 294.04K | 122.20K | 47.73K | 41.13K | 178.70K | 125.33K | 461.64K | 400.00K | 600.00K | 600.00K | 400.00K | 500.00K | 100.00K | 0.00 | 100.00K | 0.00 | 0.00 | 0.00 | 500.00K |
| Income Before Tax | -3.44M | -1.04M | -821.00K | -6.21M | 3.06M | 7.65M | 8.18M | 9.98M | 1.35M | 4.63M | 5.80M | 4.94M | 5.81M | 4.44M | 2.63M | 5.01M | 7.56M | 7.86M | 6.45M | 4.38M | 1.98M | 2.11M | 448.53K | 2.89M | 3.90M | 3.90M | 3.60M | 2.80M | 1.70M | 1.90M | 0.00 | -400.00K | 0.00 | 0.00 | 0.00 | -1.90M |
| Income Before Tax Ratio | -15.56% | -4.12% | -3.30% | -29.05% | 8.11% | 17.93% | 20.60% | 25.59% | 4.99% | 15.86% | 21.58% | 19.58% | 24.10% | 22.07% | 15.51% | 21.85% | 30.75% | 33.54% | 30.15% | 23.12% | 12.37% | 13.16% | 2.85% | 15.04% | 19.90% | 22.03% | 23.38% | 22.95% | 16.83% | 21.84% | 0.00% | -10.00% | 0.00% | 0.00% | 0.00% | -1,900.00% |
| Income Tax Expense | 716.00K | 44.00K | -156.00K | -2.35M | 1.51M | 3.07M | 2.06M | 3.30M | -164.39K | 1.43M | 1.99M | 1.96M | 2.32M | 1.82M | 1.10M | 2.05M | 3.07M | 2.96M | 2.40M | 1.62M | 760.80K | 859.00K | 216.00K | 1.19M | 1.60M | 1.50M | 1.10M | 300.00K | 100.00K | 100.00K | 0.00 | -100.00K | 100.00K | 0.00 | -100.00K | -300.00K |
| Net Income | -4.15M | -1.08M | -665.00K | -3.86M | 1.54M | 4.58M | 6.12M | 6.68M | 1.51M | 3.21M | 3.81M | 2.98M | 3.49M | 2.61M | 1.53M | 2.97M | 4.48M | 4.90M | 4.05M | 2.76M | 1.22M | 1.26M | 232.53K | 1.70M | 2.30M | 2.40M | 2.50M | 2.50M | 1.60M | 1.80M | 1.00M | -500.00K | -1.50M | -2.10M | -1.00M | -1.80M |
| Net Income Ratio | -18.80% | -4.29% | -2.67% | -18.07% | 4.09% | 10.74% | 15.42% | 17.13% | 5.60% | 10.98% | 14.16% | 11.81% | 14.48% | 13.00% | 9.01% | 12.94% | 18.25% | 20.93% | 18.93% | 14.59% | 7.62% | 7.81% | 1.48% | 8.84% | 11.73% | 13.56% | 16.23% | 20.49% | 15.84% | 20.69% | 15.15% | -12.50% | -60.00% | -123.53% | -333.33% | -1,800.00% |
| EPS | -0.72 | -0.19 | -0.12 | -0.70 | 0.28 | 0.83 | 1.11 | 1.23 | 0.28 | 0.60 | 0.72 | 0.57 | 0.67 | 0.50 | 0.29 | 0.57 | 0.86 | 0.95 | 0.79 | 0.54 | 0.23 | 0.24 | 0.04 | 0.32 | 0.44 | 0.44 | 0.44 | 0.44 | 0.27 | 1.55 | 0.93 | -0.13 | -0.39 | -0.71 | -0.39 | -1.10 |
| EPS Diluted | -0.72 | -0.19 | -0.12 | -0.70 | 0.28 | 0.83 | 1.10 | 1.22 | 0.28 | 0.60 | 0.72 | 0.57 | 0.67 | 0.50 | 0.29 | 0.57 | 0.85 | 0.94 | 0.78 | 0.54 | 0.23 | 0.24 | 0.04 | 0.32 | 0.44 | 0.44 | 0.44 | 0.44 | 0.27 | 1.40 | 0.78 | -0.13 | -0.39 | -0.71 | -0.39 | -1.10 |
| Weighted Avg Shares Out | 5.74M | 5.63M | 5.55M | 5.52M | 5.51M | 5.51M | 5.49M | 5.45M | 5.41M | 5.36M | 5.30M | 5.26M | 5.23M | 5.21M | 5.19M | 5.22M | 5.21M | 5.17M | 5.16M | 5.13M | 5.19M | 5.26M | 5.29M | 5.31M | 5.46M | 5.55M | 5.49M | 5.54M | 5.85M | 5.02M | 3.87M | 3.87M | 3.82M | 2.94M | 2.60M | 1.63M |
| Weighted Avg Shares Out (Dil) | 5.74M | 5.63M | 5.55M | 5.52M | 5.53M | 5.52M | 5.56M | 5.48M | 5.41M | 5.38M | 5.32M | 5.27M | 5.24M | 5.23M | 5.20M | 5.25M | 5.30M | 5.24M | 5.17M | 5.13M | 5.20M | 5.28M | 5.34M | 5.37M | 5.51M | 5.65M | 5.64M | 5.54M | 5.85M | 5.02M | 3.87M | 3.87M | 3.82M | 2.94M | 2.60M | 1.63M |
Psychemedics: Market Leader, 8% FCF Yield, Possible Takeover Target
Market-leading drug testing company, 30 years history, drug abuse increasing in the US. 13x P/E, 8% FCF yield on “normal” 2023 estimates.
Psychemedics Corporation Reports Stronger Second Quarter 2021 Financial Results
ACTON, Mass., Aug. 10, 2021 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ:PMD), the world's largest provider of hair testing for drugs of abuse, today announced financial results for the second quarter ended June 30, 2021.
Montana Advisors Writes Open Letter to Psychemedics
MIAMI--(BUSINESS WIRE)---- $PMD--Montana Advisors issues open letter to Psychemedics CEO (Nasdaq: PMD): Dear Kubacki: It was a pleasure speaking with you two months ago via Zoom. I appreciate the time you have given me to discuss Psychemedics Corp. (PMD or...
Psychemedics Corporation Reports First Quarter 2021 Financial Results
ACTON, Mass., May 10, 2021 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ:PMD), the world's largest provider of hair testing for drugs of abuse, today announced financial results for the first quarter ended March 31, 2021.
Psychemedics Corporation Reports Fourth Quarter and Full Year 2020 Financial Results
ACTON, Mass., March 23, 2021 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ:PMD), the world's largest provider of hair testing for drugs of abuse, today announced fourth quarter and full year financial results for the period ended December 31, 2020.
Robyn C. Davis Joins Psychemedics Board of Directors
ACTON, Mass., March 17, 2021 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ: PMD) announced that Robyn C. Davis was unanimously elected to serve on the Board of Directors of Psychemedics Corporation effective immediately. Ms. Davis will be filling the vacancy created...
Andrew Limbek Joins Psychemedics Corporation as Vice President, Controller
ACTON, Mass., Jan. 26, 2021 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ: PMD) announced that Andrew Limbek has joined the Company as Vice President, Controller.
Psychemedics Announces Third Quarter Results
ACTON, Mass., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ:PMD) today announced third quarter financial results for the period ended September 30, 2020.
Source: https://incomestatements.info
Category: Stock Reports